Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.

Scientific reports·2026
Same author

Gut microbiota in chronic inflammation: the interplay with lipid mediators.

Gut microbes·2026
Same author

Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression.

Science advances·2026
Same author

CD163 and Tim-4 identify resident intestinal macrophages that are spatially regulated by TGF-β.

The Journal of experimental medicine·2026
Same author

Publisher Correction: F- and G-actin homeostasis regulates mechanosensitive actin nucleation by formins.

Nature cell biology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025

Related Experiment Video

Updated: Jun 17, 2026

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Prostaglandin E2, an immunoactivator.

Daiji Sakata1, Chengcan Yao, Shuh Narumiya

  • 1Department of Pharmacology, Kyoto University Faculty of Medicine, Japan.

Journal of Pharmacological Sciences
|January 7, 2010
PubMed
Summary

Prostaglandin E2 (PGE2) may promote immune inflammation, contrary to traditional views. Targeting its receptors (EP4) shows promise for treating inflammatory diseases like rheumatoid arthritis.

Area of Science:

  • Immunology
  • Pharmacology
  • Molecular Biology

Background:

  • Immune-mediated inflammatory diseases (rheumatoid arthritis, multiple sclerosis, Crohn's disease) are challenging to treat.
  • Prostaglandin E2 (PGE2) is a widely produced molecule with diverse biological functions.
  • PGE2 was traditionally considered immunosuppressive due to in vitro T cell inhibition.

Purpose of the Study:

  • To investigate the in vivo role of PGE2 in immune responses.
  • To explore the function of PGE2 in T helper cell differentiation.
  • To evaluate the therapeutic potential of targeting PGE2 receptors.

Main Methods:

  • Investigated PGE2 effects on T helper cell subsets (Th1, Th17) in human and mouse models.
  • Utilized cAMP measurements and PGE receptor (EP2, EP4) signaling pathways.

More Related Videos

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

  • Administered EP4 antagonists in mouse models of experimental allergic encephalomyelitis and contact hypersensitivity.

    • Main Results:

    • PGE2, via EP2 and EP4 receptors, promotes Th17 cell expansion and can induce Th1 differentiation.
    • These findings challenge the traditional view of PGE2 as solely immunosuppressive.
    • EP4 antagonist administration suppressed disease progression and Th17 cell development in experimental models.

    Conclusions:

    • PGE2 may act as a mediator of immune inflammation in vivo.
    • EP4 antagonists demonstrate potential as novel immunomodulatory drugs for inflammatory diseases.